MBS-314

N/A

Report date: 2026/03/19 17:16:06

Base Information

Drug NameMBS-314
Drug Alias NameMBS-314
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-CD3 +[5] 
TargetsT cell surface glycoprotein CD3B-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Mabworks Biotech Co LtdKYinno Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A